Skip to main content
. 2021 Nov 8;89(1):93–103. doi: 10.1007/s00280-021-04358-3

Fig. 1.

Fig. 1

*CD3+ binding assays and interleukin-2 (IL-2) stimulation assays demonstrate PD-1 receptor occupancy by dostarlimab following administration of dostarlimab 1, 3, and 10 mg/kg (CD3+ : A; IL-2: B) and dostarlimab 500 mg Q3W (CD3+ : C; IL-2: D) and 1000 mg Q6W (CD3+ : E; IL-2: F). *Anomalous data were observed infrequently within the data sets; however, no obvious issue in sample handling or processing could be identified